WhaleCreep

5AM Venture Management, LLC 13F holdings, Q4 2025

Holdings as of December 31, 2025 · filings on SEC EDGAR · latest filing →

5AM Venture Management, LLC disclosed 21 US equity positions worth $318.1m in its Q4 2025 13F filing. The largest position was TRDA at 13.1% of the reported book, followed by CAMP and TYRA. Against the Q3 2025 filing, it opened 1 new position, added to 6 and reduced 2 among the top 21 holdings.

← Q3 2025 · Q1 2026 →

What did 5AM Venture Management, LLC own in Q4 2025? Top 21 positions

#StockSectorWeightValueSharesΔ sharesvs Q3 2025
1 TRDA ENTRADA THERAPEUTICS INC 13.1%$41.7m4,056,379 -5% reduced
2 CAMP CAMP4 THERAPEUTICS CORP 11.3%$36.0m5,869,091 0% held
3 TYRA TYRA BIOSCIENCES INC Healthcare 8.5%$27.1m1,029,298 10% added
4 VRDN VIRIDIAN THERAPEUTICS INC Healthcare 7.2%$22.9m736,595 0% held
5 PHVS PHARVARIS N V 7.0%$22.1m797,600 0% held
6 ERAS ERASCA INC Healthcare 6.3%$20.1m5,405,404 0% held
7 EYPT EYEPOINT INC Healthcare 6.0%$19.2m1,050,000 0% held
8 MPLT MAPLIGHT THERAPEUTICS INC 5.2%$16.7m950,011 – new
9 CNTA CENTESSA PHARMACEUTICALS PLC 4.6%$14.5m580,945 -15% reduced
10 CLDX CELLDEX THERAPEUTICS INC NEW Healthcare 4.2%$13.5m497,270 0% held
11 TECX TECTONIC THERAPEUTIC INC Healthcare 4.0%$12.7m606,660 19% added
12 ELVN ENLIVEN THERAPEUTICS INC Healthcare 3.7%$11.9m772,477 0% held
13 ARTV ARTIVA BIOTHERAPEUTICS INC 3.2%$10.1m2,353,304 0% held
14 SRZN SURROZEN INC 2.8%$8.8m387,500 25% added
15 BHVN BIOHAVEN LTD Healthcare 2.6%$8.3m738,972 54% added
16 TARA PROTARA THERAPEUTICS INC 2.3%$7.3m1,369,782 71% added
17 GHRS GH RESEARCH PLC 2.3%$7.3m572,665 0% held
18 SKYE SKYE BIOSCIENCE INC 2.3%$7.3m9,681,763 0% held
19 ZNTL ZENTALIS PHARMACEUTICALS INC Healthcare 1.7%$5.3m3,947,913 706% added
20 SLN SILENCE THERAPEUTICS PLC 0.9%$2.9m476,200 0% held
21 RLYB RALLYBIO CORP 0.8%$2.5m3,630,724 0% held

Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.